{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T15:27:28Z","timestamp":1781969248331,"version":"3.54.5"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1038\/s41585-023-00842-y","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T18:02:48Z","timestamp":1706724168000},"page":"339-356","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Management of patients with muscle-invasive bladder cancer with clinical evidence of pelvic lymph node metastases"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4602-8351","authenticated-orcid":false,"given":"Elisabeth","family":"Grobet-Jeandin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Lenfant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"Pinar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Mozer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphaele","family":"Renard-Penna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Seisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"key":"842_CR1","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","volume":"79","author":"JA Witjes","year":"2021","unstructured":"Witjes, J. A. et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur. Urol. 79, 82\u2013104 (2021).","journal-title":"Eur. Urol."},{"key":"842_CR2","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/JU.0000000000002242","volume":"207","author":"AP Mitra","year":"2022","unstructured":"Mitra, A. P. et al. Management trends and outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder: evolution of the university of Southern California experience over 3,347 cases. J. Urol. 207, 302\u2013313 (2022).","journal-title":"J. Urol."},{"key":"842_CR3","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1053\/j.seminoncol.2012.08.007","volume":"39","author":"J Bellmunt","year":"2012","unstructured":"Bellmunt, J. & Petrylak, D. P. New therapeutic challenges in advanced bladder cancer. Semin. Oncol. 39, 598\u2013607 (2012).","journal-title":"Semin. Oncol."},{"key":"842_CR4","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","volume":"19","author":"JP Stein","year":"2001","unstructured":"Stein, J. P. et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19, 666\u2013675 (2001).","journal-title":"J. Clin. Oncol."},{"key":"842_CR5","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.eururo.2012.02.028","volume":"61","author":"RE Hautmann","year":"2012","unstructured":"Hautmann, R. E., de Petriconi, R. C., Pfeiffer, C. & Volkmer, B. G. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur. Urol. 61, 1039\u20131047 (2012).","journal-title":"Eur. Urol."},{"key":"842_CR6","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00345-014-1355-9","volume":"33","author":"T Horn","year":"2015","unstructured":"Horn, T. et al. Clinical prognosticators of survival in patients with urothelial carcinoma of the bladder and lymph node metastases after cystectomy with curative intent. World J. Urol. 33, 813\u2013819 (2015).","journal-title":"World J. Urol."},{"key":"842_CR7","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.eururo.2009.05.014","volume":"57","author":"G Swinnen","year":"2010","unstructured":"Swinnen, G. et al. FDG-PET\/CT for the preoperative lymph node staging of invasive bladder cancer. Eur. Urol. 57, 641\u2013647 (2010).","journal-title":"Eur. Urol."},{"key":"842_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-016-0618-y","volume":"17","author":"CM Hugen","year":"2016","unstructured":"Hugen, C. M., Duddalwar, V. & Daneshmand, S. Preoperative imaging for clinical staging prior to radical cystectomy. Curr. Urol. Rep. 17, 62 (2016).","journal-title":"Curr. Urol. Rep."},{"key":"842_CR9","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.juro.2010.05.037","volume":"184","author":"RE Hautmann","year":"2010","unstructured":"Hautmann, R. E., de Petriconi, R. C. & Volkmer, B. G. Lessons learned from 1,000 neobladders: the 90-day complication rate. J. Urol. 184, 990\u2013994 (2010).","journal-title":"J. Urol."},{"key":"842_CR10","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/S0022-5347(05)67522-2","volume":"163","author":"ML Paik","year":"2000","unstructured":"Paik, M. L., Scolieri, M. J., Brown, S. L., Spirnak, J. P. & Resnick, M. I. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J. Urol. 163, 1693\u20131696 (2000).","journal-title":"J. Urol."},{"key":"842_CR11","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1007\/s00259-005-1886-9","volume":"32","author":"O Drieskens","year":"2005","unstructured":"Drieskens, O. et al. FDG-PET for preoperative staging of bladder cancer. Eur. J. Nucl. Med. Mol. Imaging 32, 1412\u20131417 (2005).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"842_CR12","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s00345-011-0817-6","volume":"30","author":"S Tritschler","year":"2012","unstructured":"Tritschler, S. et al. Staging of muscle-invasive bladder cancer: can computerized tomography help us to decide on local treatment? World J. Urol. 30, 827\u2013831 (2012).","journal-title":"World J. Urol."},{"key":"842_CR13","doi-asserted-by":"publisher","first-page":"78303","DOI":"10.21037\/tau.2018.08.28","volume":"7","author":"M Fr\u0105czek","year":"2018","unstructured":"Fr\u0105czek, M. et al. Evaluation of lymph node status in patients with urothelial carcinoma \u2014 still in search of the perfect imaging modality: a systematic review. Transl. Androl. Urol. 7, 78303\u201378803 (2018).","journal-title":"Transl. Androl. Urol."},{"key":"842_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000440889","volume":"96","author":"T Horn","year":"2016","unstructured":"Horn, T. et al. Evaluation of computed tomography for lymph node staging in bladder cancer prior to radical cystectomy. Urol. Int. 96, 51\u201356 (2016).","journal-title":"Urol. Int."},{"key":"842_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1148\/radiology.180.2.2068292","volume":"180","author":"RE Dorfman","year":"1991","unstructured":"Dorfman, R. E., Alpern, M. B., Gross, B. H. & Sandler, M. A. Upper abdominal lymph nodes: criteria for normal size determined with CT. Radiology 180, 319\u2013322 (1991).","journal-title":"Radiology"},{"key":"842_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s40880-018-0269-0","volume":"37","author":"Y Li","year":"2018","unstructured":"Li, Y. et al. Computed tomography and magnetic resonance imaging evaluation of pelvic lymph node metastasis in bladder cancer. Chin. J. Cancer 37, 3 (2018).","journal-title":"Chin. J. Cancer"},{"key":"842_CR17","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00345-018-2439-8","volume":"37","author":"J Crozier","year":"2019","unstructured":"Crozier, J. et al. Comparative sensitivity and specificity of imaging modalities in staging bladder cancer prior to radical cystectomy: a systematic review and meta-analysis. World J. Urol. 37, 667\u2013690 (2019).","journal-title":"World J. Urol."},{"key":"842_CR18","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00345-015-1654-9","volume":"34","author":"SC Schmid","year":"2016","unstructured":"Schmid, S. C. et al. Prognostic value of computed tomography before radical cystectomy in patients with invasive bladder cancer: imaging predicts survival. World J. Urol. 34, 569\u2013576 (2016).","journal-title":"World J. Urol."},{"key":"842_CR19","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.euf.2016.11.005","volume":"4","author":"M Moschini","year":"2018","unstructured":"Moschini, M. et al. Clinical lymphadenopathy in urothelial cancer: a transatlantic collaboration on performance of cross-sectional imaging and oncologic outcomes in patients treated with radical cystectomy without neoadjuvant chemotherapy. Eur. Urol. Focus 4, 245\u2013251 (2018).","journal-title":"Eur. Urol. Focus"},{"key":"842_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.euf.2016.04.010","volume":"2","author":"V Panebianco","year":"2016","unstructured":"Panebianco, V. et al. Improving staging in bladder cancer: the increasing role of multiparametric magnetic resonance imaging. Eur. Urol. Focus 2, 113\u2013121 (2016).","journal-title":"Eur. Urol. Focus"},{"key":"842_CR21","doi-asserted-by":"publisher","first-page":"W95","DOI":"10.2214\/AJR.17.18481","volume":"210","author":"S Woo","year":"2018","unstructured":"Woo, S., Suh, C. H., Kim, S. Y., Cho, J. Y. & Kim, S. H. The diagnostic performance of MRI for detection of lymph node metastasis in bladder and prostate cancer: an updated systematic review and diagnostic meta-analysis. AJR Am. J. Roentgenol. 210, W95\u2013W109 (2018).","journal-title":"AJR Am. J. Roentgenol."},{"key":"842_CR22","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.eururo.2018.04.029","volume":"74","author":"V Panebianco","year":"2018","unstructured":"Panebianco, V. et al. Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur. Urol. 74, 294\u2013306 (2018).","journal-title":"Eur. Urol."},{"key":"842_CR23","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1111\/j.1464-410X.2012.11129.x","volume":"110","author":"DA Green","year":"2012","unstructured":"Green, D. A. et al. Role of magnetic resonance imaging in bladder cancer: current status and emerging techniques. BJU Int. 110, 1463\u20131470 (2012).","journal-title":"BJU Int."},{"key":"842_CR24","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1111\/j.1464-410X.2011.10446.x","volume":"109","author":"R Papalia","year":"2012","unstructured":"Papalia, R. et al. Diffusion-weighted magnetic resonance imaging in patients selected for radical cystectomy: detection rate of pelvic lymph node metastases. BJU Int. 109, 1031\u20131036 (2012).","journal-title":"BJU Int."},{"key":"842_CR25","first-page":"7454","volume":"21","author":"DA Wollin","year":"2014","unstructured":"Wollin, D. A., Deng, F.-M., Huang, W. C., Babb, J. S. & Rosenkrantz, A. B. Conventional and diffusion-weighted MRI features in diagnosis of metastatic lymphadenopathy in bladder cancer. Can. J. Urol. 21, 7454\u20137459 (2014).","journal-title":"Can. J. Urol."},{"key":"842_CR26","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1754-9485.2010.02182.x","volume":"54","author":"N Mir","year":"2010","unstructured":"Mir, N., Sohaib, S. A., Collins, D. & Koh, D. M. Fusion of high b-value diffusion-weighted and T2-weighted MR images improves identification of lymph nodes in the pelvis. J. Med. Imaging Radiat. Oncol. 54, 358\u2013364 (2010).","journal-title":"J. Med. Imaging Radiat. Oncol."},{"key":"842_CR27","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.urology.2012.07.056","volume":"80","author":"S Daneshmand","year":"2012","unstructured":"Daneshmand, S., Ahmadi, H., Huynh, L. N. & Dobos, N. Preoperative staging of invasive bladder cancer with dynamic gadolinium-enhanced magnetic resonance imaging: results from a prospective study. Urology 80, 1313\u20131318 (2012).","journal-title":"Urology"},{"key":"842_CR28","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s00345-016-1772-z","volume":"34","author":"A Soubra","year":"2016","unstructured":"Soubra, A. et al. The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: a single-institution study and a systematic review with meta-analysis. World J. Urol. 34, 1229\u20131237 (2016).","journal-title":"World J. Urol."},{"key":"842_CR29","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/j.1464-410X.2010.09212.x","volume":"106","author":"M Lodde","year":"2010","unstructured":"Lodde, M. et al. Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma. BJU Int. 106, 658\u2013663 (2010).","journal-title":"BJU Int."},{"key":"842_CR30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4103\/1450-1147.138572","volume":"13","author":"D Chakraborty","year":"2014","unstructured":"Chakraborty, D. et al. Role of fluorodeoxyglucose positron emission tomography\/computed tomography in diagnostic evaluation of carcinoma urinary bladder: comparison with computed tomography. World J. Nucl. Med. 13, 34\u201339 (2014).","journal-title":"World J. Nucl. Med."},{"key":"842_CR31","doi-asserted-by":"publisher","first-page":"4286","DOI":"10.1007\/s00330-018-5959-0","volume":"29","author":"A Girard","year":"2019","unstructured":"Girard, A. et al. Integrated analysis of 18F-FDG PET\/CT improves preoperative lymph node staging for patients with invasive bladder cancer. Eur. Radiol. 29, 4286\u20134293 (2019).","journal-title":"Eur. Radiol."},{"key":"842_CR32","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1016\/j.ejso.2014.08.479","volume":"40","author":"M Rouanne","year":"2014","unstructured":"Rouanne, M. et al. Potential impact of 18F-FDG PET\/CT on patients selection for neoadjuvant chemotherapy before radical cystectomy. Eur. J. Surg. Oncol. 40, 1724\u20131730 (2014).","journal-title":"Eur. J. Surg. Oncol."},{"key":"842_CR33","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.euf.2017.06.005","volume":"5","author":"S Vind-Kezunovic","year":"2019","unstructured":"Vind-Kezunovic, S. et al. Detection of lymph node metastasis in patients with bladder cancer using maximum standardised uptake value and 18F-fluorodeoxyglucose positron emission tomography\/computed tomography: results from a high-volume centre including long-term follow-up. Eur. Urol. Focus 5, 90\u201396 (2019).","journal-title":"Eur. Urol. Focus"},{"key":"842_CR34","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1200\/JCO.2008.20.6722","volume":"27","author":"AS Kibel","year":"2009","unstructured":"Kibel, A. S. et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography\/computed tomography for staging of muscle-invasive bladder carcinoma. J. Clin. Oncol. 27, 4314\u20134320 (2009).","journal-title":"J. Clin. Oncol."},{"key":"842_CR35","doi-asserted-by":"publisher","first-page":"3973","DOI":"10.1200\/JCO.2010.28.7052","volume":"28","author":"AB Apolo","year":"2010","unstructured":"Apolo, A. B. et al. Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography\/computed tomography in bladder cancer. J. Clin. Oncol. 28, 3973\u20133978 (2010).","journal-title":"J. Clin. Oncol."},{"key":"842_CR36","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.euo.2021.01.005","volume":"5","author":"CS Voskuilen","year":"2022","unstructured":"Voskuilen, C. S. et al. Staging 18F-fluorodeoxyglucose positron emission tomography\/computed tomography changes treatment recommendation in invasive bladder cancer. Eur. Urol. Oncol. 5, 366\u2013369 (2022).","journal-title":"Eur. Urol. Oncol."},{"key":"842_CR37","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/iju.12045","volume":"20","author":"M Hitier-Berthault","year":"2013","unstructured":"Hitier-Berthault, M. et al. 18F-fluorodeoxyglucose positron emission tomography-computed tomography for preoperative lymph node staging in patients undergoing radical cystectomy for bladder cancer: a prospective study. Int J. Urol. 20, 788\u2013796 (2013).","journal-title":"Int J. Urol."},{"key":"842_CR38","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/JU.0000000000001006","volume":"204","author":"S Dason","year":"2020","unstructured":"Dason, S. et al. Utility of routine preoperative 18F-fluorodeoxyglucose positron emission tomography\/computerized tomography in identifying pathological lymph node metastases at radical cystectomy. J. Urol. 204, 254\u2013259 (2020).","journal-title":"J. Urol."},{"key":"842_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-015-0080-z","volume":"15","author":"F Aljabery","year":"2015","unstructured":"Aljabery, F. et al. PET\/CT versus conventional CT for detection of lymph node metastases in patients with locally advanced bladder cancer. BMC Urol. 15, 87 (2015).","journal-title":"BMC Urol."},{"key":"842_CR40","doi-asserted-by":"publisher","first-page":"e387","DOI":"10.1016\/j.clgc.2016.08.009","volume":"15","author":"R Pichler","year":"2017","unstructured":"Pichler, R. et al. Pelvic lymph node staging by combined 18F-FDG-PET\/CT imaging in bladder cancer prior to radical cystectomy. Clin. Genitourin. Cancer 15, e387\u2013e395 (2017).","journal-title":"Clin. Genitourin. Cancer"},{"key":"842_CR41","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/bju.12608","volume":"114","author":"H Goodfellow","year":"2014","unstructured":"Goodfellow, H. et al. Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer. BJU Int. 114, 389\u2013395 (2014).","journal-title":"BJU Int."},{"key":"842_CR42","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1245\/s10434-015-4369-7","volume":"22","author":"IG Jeong","year":"2015","unstructured":"Jeong, I. G. et al. FDG PET-CT for lymph node staging of bladder cancer: a prospective study of patients with extended pelvic lymphadenectomy. Ann. Surg. Oncol. 22, 3150\u20133156 (2015).","journal-title":"Ann. Surg. Oncol."},{"key":"842_CR43","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000488200","volume":"95","author":"HK Ha","year":"2018","unstructured":"Ha, H. K., Koo, P. J. & Kim, S.-J. Diagnostic accuracy of F-18 FDG PET\/CT for preoperative lymph node staging in newly diagnosed bladder cancer patients: a systematic review and meta-analysis. Oncology 95, 31\u201338 (2018).","journal-title":"Oncology"},{"key":"842_CR44","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","volume":"14","author":"P Lambin","year":"2017","unstructured":"Lambin, P. et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat. Rev. Clin. Oncol. 14, 749\u2013762 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"842_CR45","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ebiom.2018.07.029","volume":"34","author":"S Wu","year":"2018","unstructured":"Wu, S. et al. Development and validation of an MRI-based radiomics signature for the preoperative prediction of lymph node metastasis in bladder cancer. EBioMedicine 34, 76\u201384 (2018).","journal-title":"EBioMedicine"},{"key":"842_CR46","first-page":"00204","volume":"S2405-4569","author":"E Gresser","year":"2022","unstructured":"Gresser, E. et al. Radiomics signature using manual versus automated segmentation for lymph node staging of bladder cancer. Eur. Urol. Focus S2405-4569, 00204\u201300208 (2022).","journal-title":"Eur. Urol. Focus"},{"key":"842_CR47","doi-asserted-by":"crossref","unstructured":"Harmon, S. A. et al. Multiresolution application of artificial intelligence in digital pathology for prediction of positive lymph nodes from primary tumors in bladder cancer. JCO Clin. Cancer Inform. 4, 367\u2013382 (2020).","DOI":"10.1200\/CCI.19.00155"},{"key":"842_CR48","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.juro.2016.04.061","volume":"196","author":"R Seiler","year":"2016","unstructured":"Seiler, R. et al. Prediction of lymph node metastasis in patients with bladder cancer using whole transcriptome gene expression signatures. J. Urol. 196, 1036\u20131041 (2016).","journal-title":"J. Urol."},{"key":"842_CR49","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s11307-022-01715-3","volume":"24","author":"E Novruzov","year":"2022","unstructured":"Novruzov, E. et al. Head-to-head intra-individual comparison of [68Ga]-FAPI and [18F]-FDG PET\/CT in patients with bladder cancer. Mol. Imaging Biol. 24, 651\u2013658 (2022).","journal-title":"Mol. Imaging Biol."},{"key":"842_CR50","first-page":"606","volume":"16","author":"J Zhang-Yin","year":"2023","unstructured":"Zhang-Yin, J. et al. PET imaging in bladder cancer: an update and future direction. Pharm. Basel Switz. 16, 606 (2023).","journal-title":"Pharm. Basel Switz."},{"key":"842_CR51","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","volume":"33","author":"T Powles","year":"2022","unstructured":"Powles, T. et al. Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 244\u2013258 (2022).","journal-title":"Ann. Oncol."},{"key":"842_CR52","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","volume":"198","author":"SS Chang","year":"2017","unstructured":"Chang, S. S. et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline. J. Urol. 198, 552\u2013559 (2017).","journal-title":"J. Urol."},{"key":"842_CR53","doi-asserted-by":"crossref","unstructured":"Bladder cancer: diagnosis and management of bladder cancer: \u00a9 NICE (2015) Bladder cancer: diagnosis and management of bladder cancer. BJU Int. 120:755\u2013765 (2017).","DOI":"10.1111\/bju.14045"},{"key":"842_CR54","doi-asserted-by":"publisher","first-page":"329","DOI":"10.6004\/jnccn.2020.0011","volume":"18","author":"TW Flaig","year":"2020","unstructured":"Flaig, T. W. et al. Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J. Natl Compr. Cancer Netw. 18, 329\u2013354 (2020).","journal-title":"J. Natl Compr. Cancer Netw."},{"key":"842_CR55","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","volume":"48","author":"Advanced Bladder Cancer (ABC) Meta-analysis Collaboration.","year":"2005","unstructured":"Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur. Urol. 48, 202\u2013205 (2005). discussion 205\u2013206.","journal-title":"Eur. Urol."},{"key":"842_CR56","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.urolonc.2017.10.002","volume":"36","author":"O Fahmy","year":"2018","unstructured":"Fahmy, O. et al. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Urol. Oncol. 36, 43\u201353 (2018).","journal-title":"Urol. Oncol."},{"key":"842_CR57","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman, H. B. et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859\u2013866 (2003).","journal-title":"N. Engl. J. Med."},{"key":"842_CR58","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","volume":"79","author":"C Pfister","year":"2021","unstructured":"Pfister, C. et al. Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer. analysis of the GETUG\/AFU V05 VESPER trial secondary endpoints: chemotherapy toxicity and pathological responses. Eur. Urol. 79, 214\u2013221 (2021).","journal-title":"Eur. Urol."},{"key":"842_CR59","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.clgc.2020.02.014","volume":"18","author":"G Iyer","year":"2020","unstructured":"Iyer, G. et al. Neoadjuvant gemcitabine-cisplatin plus radical cystectomy-pelvic lymph node dissection for muscle-invasive bladder cancer: a 12-year experience. Clin. Genitourin. Cancer 18, 387\u2013394 (2020).","journal-title":"Clin. Genitourin. Cancer"},{"key":"842_CR60","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.eururo.2011.12.010","volume":"61","author":"R Rosenblatt","year":"2012","unstructured":"Rosenblatt, R. et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur. Urol. 61, 1229\u20131238 (2012).","journal-title":"Eur. Urol."},{"key":"842_CR61","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.urology.2013.08.082","volume":"83","author":"RP Meijer","year":"2014","unstructured":"Meijer, R. P. et al. Induction chemotherapy followed by surgery in node positive bladder cancer. Urology 83, 134\u2013139 (2014).","journal-title":"Urology"},{"key":"842_CR62","doi-asserted-by":"publisher","first-page":"59.e1","DOI":"10.1016\/j.urolonc.2015.08.012","volume":"34","author":"PL Ho","year":"2016","unstructured":"Ho, P. L. et al. Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: the M.D. Anderson Cancer Center Experience. Urol. Oncol. 34, 59.e1\u20138 (2016).","journal-title":"Urol. Oncol."},{"key":"842_CR63","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s10147-015-0839-y","volume":"20","author":"S Urakami","year":"2015","unstructured":"Urakami, S. et al. Clinical response to induction chemotherapy predicts improved survival outcome in urothelial carcinoma with clinical lymph nodal metastasis treated by consolidative surgery. Int. J. Clin. Oncol. 20, 1171\u20131178 (2015).","journal-title":"Int. J. Clin. Oncol."},{"key":"842_CR64","doi-asserted-by":"publisher","first-page":"287","DOI":"10.4149\/neo_2018_170403N239","volume":"65","author":"M Stanik","year":"2018","unstructured":"Stanik, M. et al. Clinically node-positive bladder cancer: oncological results of induction chemotherapy and consolidative surgery. Neoplasma 65, 287\u2013291 (2018).","journal-title":"Neoplasma"},{"key":"842_CR65","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/bju.15374","volume":"129","author":"J Abrahamsson","year":"2022","unstructured":"Abrahamsson, J. et al. Complete metabolic response with [18F]fluorodeoxyglucose-positron emission tomography\/computed tomography predicts survival following induction chemotherapy and radical cystectomy in clinically lymph node positive bladder cancer. BJU Int. 129, 174\u2013181 (2022).","journal-title":"BJU Int."},{"key":"842_CR66","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.juro.2015.07.085","volume":"195","author":"K Zargar-Shoshtari","year":"2016","unstructured":"Zargar-Shoshtari, K. et al. A multi-institutional analysis of outcomes of patients with clinically node positive urothelial bladder cancer treated with induction chemotherapy and radical cystectomy. J. Urol. 195, 53\u201359 (2016).","journal-title":"J. Urol."},{"key":"842_CR67","doi-asserted-by":"publisher","first-page":"76.e19","DOI":"10.1016\/j.urolonc.2019.09.003","volume":"38","author":"O Al-Alao","year":"2020","unstructured":"Al-Alao, O. et al. Clinically node-positive (cN+) urothelial carcinoma of the bladder treated with chemotherapy and radical cystectomy: clinical outcomes and development of a postoperative risk stratification model. Urol. Oncol. 38, 76.e19\u201376.e28 (2020).","journal-title":"Urol. Oncol."},{"key":"842_CR68","doi-asserted-by":"publisher","unstructured":"von Deimling, M. et al. Impact of the extent of lymph node dissection on survival outcomes in clinically lymph node\u2010positive bladder cancer. BJU International https:\/\/doi.org\/10.1111\/bju.16210 (2023).","DOI":"10.1111\/bju.16210"},{"key":"842_CR69","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.clon.2019.07.017","volume":"32","author":"MP Tan","year":"2020","unstructured":"Tan, M. P. et al. The intensity-modulated pelvic node and bladder radiotherapy (IMPART) trial: a phase II single-centre prospective study. Clin. Oncol. 32, 93\u2013100 (2020).","journal-title":"Clin. Oncol."},{"key":"842_CR70","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.3892\/ijo.2014.2378","volume":"44","author":"H Azuma","year":"2014","unstructured":"Azuma, H. et al. The novel bladder preservation therapy BOAI-CDDP-radiation (OMC-regimen): a new treatment option for invasive bladder cancer patients with lymph node metastasis. Int. J. Oncol. 44, 1895\u20131903 (2014).","journal-title":"Int. J. Oncol."},{"key":"842_CR71","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin, D. F. et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N. Engl. J. Med. 384, 2102\u20132114 (2021).","journal-title":"N. Engl. J. Med."},{"key":"842_CR72","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","volume":"22","author":"J Bellmunt","year":"2021","unstructured":"Bellmunt, J. et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 22, 525\u2013537 (2021).","journal-title":"Lancet Oncol."},{"key":"842_CR73","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles, T. et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 383, 1218\u20131230 (2020).","journal-title":"N. Engl. J. Med."},{"key":"842_CR74","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt, J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 376, 1015\u20131026 (2017).","journal-title":"N. Engl. J. Med."},{"key":"842_CR75","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/S0022-5347(05)00644-0","volume":"175","author":"CT Lee","year":"2006","unstructured":"Lee, C. T. et al. Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. J. Urol. 175, 1262\u20131267 (2006).","journal-title":"J. Urol."},{"key":"842_CR76","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/bju.12829","volume":"115","author":"I Lucca","year":"2015","unstructured":"Lucca, I. et al. Adjuvant cisplatin-based combined chemotherapy for lymph node (LN)-positive urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC): a retrospective international study of >1500 patients. BJU Int. 115, 722\u2013727 (2015).","journal-title":"BJU Int."},{"key":"842_CR77","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.eururo.2008.07.018","volume":"55","author":"SM Donat","year":"2009","unstructured":"Donat, S. M. et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur. Urol. 55, 177\u2013185 (2009).","journal-title":"Eur. Urol."},{"key":"842_CR78","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.euf.2019.02.001","volume":"6","author":"S Arora","year":"2020","unstructured":"Arora, S. et al. Defining a \u201cHigh Volume\u201d radical cystectomy hospital: where do we draw the line? Eur. Urol. Focus 6, 975\u2013981 (2020).","journal-title":"Eur. Urol. Focus"},{"key":"842_CR79","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.eururo.2021.09.028","volume":"81","author":"Advanced Bladder Cancer (ABC) Meta-analysis Collaborators Group.","year":"2022","unstructured":"Advanced Bladder Cancer (ABC) Meta-analysis Collaborators Group. Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis of individual participant data from randomised controlled trials. Eur. Urol. 81, 50\u201361 (2022).","journal-title":"Eur. Urol."},{"key":"842_CR80","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00345-018-2190-1","volume":"36","author":"M Moschini","year":"2018","unstructured":"Moschini, M. et al. Surgical treatment for clinical node-positive bladder cancer patients treated with radical cystectomy without neoadjuvant chemotherapy. World J. Urol. 36, 639\u2013644 (2018).","journal-title":"World J. Urol."},{"key":"842_CR81","first-page":"00062","volume":"S2588-9311","author":"L Afferi","year":"2022","unstructured":"Afferi, L. et al. Selecting the best candidates for cisplatin-based adjuvant chemotherapy after radical cystectomy among patients with pN+ bladder cancer. Eur. Urol. Oncol. S2588-9311, 00062\u20131 (2022).","journal-title":"Eur. Urol. Oncol."},{"key":"842_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.09.015","volume":"69","author":"TJN Hermans","year":"2016","unstructured":"Hermans, T. J. N. et al. Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer \u2014 results of a nationwide population-based study. Eur. J. Cancer 69, 1\u20138 (2016).","journal-title":"Eur. J. Cancer"},{"key":"842_CR83","doi-asserted-by":"publisher","first-page":"e420","DOI":"10.1016\/j.clgc.2019.01.001","volume":"17","author":"S Pak","year":"2019","unstructured":"Pak, S. et al. Induction chemotherapy followed by surgery versus upfront radical cystectomy in patients with clinically node-positive muscle-invasive bladder cancer. Clin. Genitourin. Cancer 17, e420\u2013e428 (2019).","journal-title":"Clin. Genitourin. Cancer"},{"key":"842_CR84","doi-asserted-by":"publisher","first-page":"133.e1","DOI":"10.1016\/j.urolonc.2020.08.020","volume":"39","author":"S Ghodoussipour","year":"2021","unstructured":"Ghodoussipour, S. et al. Preoperative chemotherapy in clinically node positive muscle invasive bladder cancer: radiologic variables can predict response. Urol. Oncol. 39, 133.e1\u2013133.e8 (2021).","journal-title":"Urol. Oncol."},{"key":"842_CR85","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00345-020-03205-z","volume":"39","author":"L Afferi","year":"2021","unstructured":"Afferi, L. et al. The impact of treatment modality on survival in patients with clinical node-positive bladder cancer: results from a multicenter collaboration. World J. Urol. 39, 443\u2013451 (2021).","journal-title":"World J. Urol."},{"key":"842_CR86","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.euros.2023.02.014","volume":"51","author":"M von Deimling","year":"2023","unstructured":"von Deimling, M. et al. Carboplatin induction chemotherapy in clinically lymph node\u2013positive bladder cancer. Eur. Urol. Open Sci. 51, 39\u201346 (2023).","journal-title":"Eur. Urol. Open Sci."},{"key":"842_CR87","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.euf.2017.05.006","volume":"5","author":"A Necchi","year":"2019","unstructured":"Necchi, A. et al. Lack of effectiveness of postchemotherapy lymphadenectomy in bladder cancer patients with clinical evidence of metastatic pelvic or retroperitoneal lymph nodes only: a propensity score-based analysis. Eur. Urol. Focus 5, 242\u2013249 (2019).","journal-title":"Eur. Urol. Focus"},{"key":"842_CR88","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3233\/BLC-170137","volume":"3","author":"W Haque","year":"2017","unstructured":"Haque, W., Verma, V., Butler, E. B. & Teh, B. S. Chemotherapy versus chemoradiation for node-positive bladder cancer: practice patterns and outcomes from the national cancer data base. Bladder Cancer 3, 283\u2013291 (2017).","journal-title":"Bladder Cancer"},{"key":"842_CR89","doi-asserted-by":"crossref","unstructured":"Swinton, M. et al. Bladder-sparing treatment with radical dose radiotherapy is an effective alternative to radical cystectomy in patients with clinically node-positive nonmetastatic bladder cancer. J. Clin. Oncol. 2023:JCO2300725.","DOI":"10.1200\/JCO.23.00725"},{"key":"842_CR90","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1200\/JCO.2016.66.7352","volume":"34","author":"T Seisen","year":"2016","unstructured":"Seisen, T. et al. Efficacy of high-intensity local treatment for metastatic urothelial carcinoma of the bladder: a propensity score-weighted analysis from the national cancer data base. J. Clin. Oncol. 34, 3529\u20133536 (2016).","journal-title":"J. Clin. Oncol."},{"key":"842_CR91","first-page":"03163","volume":"S0302-2838","author":"T Seisen","year":"2023","unstructured":"Seisen, T., Roupr\u00eat, M., Trinh, Q.-D. & Bellmunt, J. Re: Martin Swinton, Neethu Billy Graham Mariam, Jean Ling Tan, et al. Bladder-sparing treatment with radical dose radiotherapy is an effective alternative to radical cystectomy in patients with clinically node-positive nonmetastatic bladder cancer. J Clin Oncol. In press. Eur. Urol. S0302-2838, 03163\u201303169 (2023).","journal-title":"Eur. Urol."},{"key":"842_CR92","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1200\/JCO.2016.67.5033","volume":"34","author":"MD Galsky","year":"2016","unstructured":"Galsky, M. D. et al. Comparative effectiveness of treatment strategies for bladder cancer with clinical evidence of regional lymph node involvement. J. Clin. Oncol. 34, 2627\u20132635 (2016).","journal-title":"J. Clin. Oncol."},{"key":"842_CR93","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.urology.2020.06.091","volume":"146","author":"C Darwish","year":"2020","unstructured":"Darwish, C., Sparks, A., Amdur, R., Reddy, A. & Whalen, M. Trends in treatment strategies and comparison of outcomes in lymph node positive bladder cancer: an analysis of the national cancer database. Urology 146, 168\u2013176 (2020).","journal-title":"Urology"},{"key":"842_CR94","doi-asserted-by":"publisher","first-page":"e759","DOI":"10.1016\/j.clgc.2019.04.007","volume":"17","author":"M Stan\u00edk","year":"2019","unstructured":"Stan\u00edk, M. et al. Comparison of different treatment modalities outcomes in clinically node-positive bladder cancer: analysis of a population-based cancer registry. Clin. Genitourin. Cancer 17, e759\u2013e767 (2019).","journal-title":"Clin. Genitourin. Cancer"},{"key":"842_CR95","doi-asserted-by":"publisher","first-page":"5431","DOI":"10.1002\/cam4.2446","volume":"8","author":"WK Bae","year":"2019","unstructured":"Bae, W. K. et al. Comparative effectiveness of palliative chemotherapy versus neoadjuvant chemotherapy followed by radical cystectomy versus cystectomy followed by adjuvant chemotherapy versus cystectomy for regional node-positive bladder cancer: a retrospective analysis: KCSG GU 17-03. Cancer Med. 8, 5431\u20135437 (2019).","journal-title":"Cancer Med."},{"key":"842_CR96","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","volume":"25","author":"T Powles","year":"2019","unstructured":"Powles, T. et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat. Med. 25, 1706\u20131714 (2019).","journal-title":"Nat. Med."},{"key":"842_CR97","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1200\/JCO.18.01148","volume":"36","author":"A Necchi","year":"2018","unstructured":"Necchi, A. et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J. Clin. Oncol. 36, 3353\u20133360 (2018).","journal-title":"J. Clin. Oncol."},{"key":"842_CR98","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1200\/JCO.21.01003","volume":"39","author":"TL Rose","year":"2021","unstructured":"Rose, T. L. et al. Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive bladder cancer. J. Clin. Oncol. 39, 3140\u20133148 (2021).","journal-title":"J. Clin. Oncol."},{"key":"842_CR99","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1200\/JCO.21.01485","volume":"40","author":"SA Funt","year":"2022","unstructured":"Funt, S. A. et al. Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: a multicenter, single-arm, phase II trial. J. Clin. Oncol. 40, 1312\u20131322 (2022).","journal-title":"J. Clin. Oncol."},{"key":"842_CR100","unstructured":"M.D. Anderson Cancer Center. Durvalumab and Standard Chemotherapy for the Treatment of Lymph Node Positive Bladder Cancer (2023). https:\/\/clinicaltrials.gov\/study\/NCT05137262 (accessed 1 January 2023)."},{"key":"842_CR101","unstructured":"ClinicalTrials.gov. National Cancer Institute (NCI). Phase II Study of Bladder-SparIng ChemoradiatioN With Durvalumab in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE) (2023). https:\/\/clinicaltrials.gov\/study\/NCT05137262 (accessed 1 January 2023)."},{"key":"842_CR102","unstructured":"Woldu S. Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer (CIRTiN-BC): A Phase II, Single-Arm Trial (2023). https:\/\/clinicaltrials.gov\/study\/NCT04779489 (accessed 1 January 2023)."},{"key":"842_CR103","unstructured":"ClinicalTrials.gov. Memorial Sloan Kettering Cancer Center. Enfortumab Vedotin in Combination With Pembrolizumab for Locally Advanced and\/or Node Positive Urothelial Carcinoma Prior to Surgery (EV-ECLIPSE) (2023). https:\/\/clinicaltrials.gov\/study\/NCT05239624 (accessed 1 January 2023)."},{"key":"842_CR104","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles, T. et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N. Engl. J. Med. 384, 1125\u20131135 (2021).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-023-00842-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-023-00842-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-023-00842-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T13:03:40Z","timestamp":1717679020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-023-00842-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":104,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["842"],"URL":"https:\/\/doi.org\/10.1038\/s41585-023-00842-y","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,31]]},"assertion":[{"value":"1 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}